Investors Sidelined as Companies Face Regulatory Scrutiny
News related to:Aardvark Therapeutics, Inc. (NASDAQ: AARD) · 3 min read
PHILADELPHIA, Sept. 22, 2026 /CourierPR/ -- Aardvark Therapeutics, Inc. (NASDAQ: AARD) has faced significant setbacks following its initial public offering (IPO) on February 13, 2025. The company's lead drug candidate, ARD-101, has been the subject of intense scrutiny following the release of a securities class action lawsuit filed against the company and its officers and directors. The lawsuit alleges that the IPO offering documents were materially false or misleading due to the failure to disclose that ARD-101 was less safe than investors had been led to believe, and its clinical, regulatory, and commercial prospects were therefore overstated.
According to the complaint, Aardvark Therapeutics, Inc. (NASDAQ: AARD) represented that ARD-101 had been "well-tolerated" in earlier clinical trials, had limited systemic absorption, and had demonstrated no serious adverse events. However, subsequent events have cast doubt on these claims. On February 27, 2026, Aardvark announced that it was voluntarily pausing enrollment and dosing in the Phase 3 HERO trial after identifying reversible cardiac observations during safety monitoring in a healthy-volunteer study. This announcement led to a significant decline in the company's stock price, which closed at $5.47 per share on March 2, 2026, representing a 56% drop from the IPO price.
The situation worsened on May 14, 2026, when Aardvark announced that the FDA had placed a full clinical hold on the investigational new drug application for ARD-101, including the Phase 3 HERO trial and its open-label extension. This announcement resulted in another substantial drop in the company's stock price, closing at $4.57 per share, a 32.1% decline from the previous day.
The lawsuit further alleges that Aardvark Therapeutics, Inc. (NASDAQ: AARD) continued to make false and misleading statements regarding ARD-101's safety after the IPO. Specifically, the company representatives described ARD-101 as having a "very, very clean" safety profile and represented that its limited systemic exposure reduced the likelihood of side effects. These representations were contradicted by the FDA's subsequent warning letter, which highlighted that any malfunction that could be life-threatening must be reported to the FDA, and any hypoglycemia requiring medical intervention was reportable.
Beta Bionics, Inc. (NASDAQ: BBNX) has also found itself in the spotlight, with Grabar Law Office investigating claims on behalf of the company's shareholders. The investigation centers around whether certain officers and directors breached their fiduciary duties to the company. According to a recently filed securities fraud class action complaint, Beta Bionics, Inc. (NASDAQ: BBNX) made false and misleading statements regarding the iLet insulin delivery device, including the FDA's concerns about its malfunctioning and dosing patients with dangerously high levels of insulin, which led to hypoglycemic events.
On January 8, 2026, after markets closed, Beta Bionics reported an unexpected miss on new iLet patient starts, which was previously reported by the Capitol Forum in December. This news caused the company's stock price to drop by 37%. On January 30, 2026, Beta Bionics filed a Form 8-K that disclosed the FDA's warning letter, which contradicted the company's previous disclosure of the FDA's concerns and issues with the iLet device.
PROCEPT BioRobotics Corporation (NASDAQ: PRCT) is also under investigation for allegedly breaching fiduciary duties to shareholders. The investigation concerns whether the company's officers and directors disclosed material adverse facts, including the use of an extensive discount program designed to incentivize customers to place bulk orders in excess of procedure demand, which artificially inflated reported U.S. handpiece unit sales and revenues.
The Simply Good Foods Company (NASDAQ: SMPL) has also been the subject of an investigation, with Grabar Law Office investigating claims on behalf of shareholders. The investigation centers around whether the company's officers and directors disclosed material adverse facts pertaining to the company's business, operations, and prospects. Specifically, the complaint alleges that the company failed to disclose that it had lost key managerial personnel following the acquisition of OWYN, which was necessary for the successful integration of the acquired OWYN assets.
In each of these cases, the companies have faced significant setbacks, with their stock prices experiencing substantial declines. Investors who purchased shares at or shortly after the respective IPOs and have continued to hold their shares are encouraged to seek corporate reforms, the return of funds back to the company, and a court-approved incentive award.